New study tracks Pill-Taking habits in early breast cancer patients

NCT ID NCT06650423

Recruiting now Knowledge-focused Sponsor: Institute of Oncology Ljubljana Source: ClinicalTrials.gov ↗

First seen Mar 28, 2026 · Last updated May 16, 2026 · Updated 8 times

Summary

This study looks at how well women with early-stage, hormone-positive breast cancer take their prescribed medications (aromatase inhibitors with or without abemaciclib). About 319 participants will be followed for 6 months to see if those on the combination therapy have lower adherence. The goal is to understand factors that affect medication-taking behavior and improve long-term treatment success.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Institute of Oncology Ljubljana
RECRUITING

Ljubljana, 1000, Slovenia

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

EARLY BREAST CANCER EARLY BREAST CANCER HER2-NEGATIVE BREAST CANCER HORMONE RECEPTOR POSITIVE TUMOR